In a phase 1/2a clinical trial (NCT03529877), 14 patients with RDEB received three intravenous infusions of 2 × 106 ABCB5+ MSCs/kg body weight on days 0, 17, and 35. The gene discussed is ABCB5; the disease is recessive dystrophic epidermolysis bullosa.